For example, miR-323-3p inhibits the expression of epidermal growth factor-like (EGF-like) and 2 follistatin domain (TMEFF2) transmembrane proteins and activates protein kinase B (PKB/AKT) and extracellular regulated protein kinases (ERK) pathways, thereby inhibiting apoptosis in non-small-cell lung carcinoma (NSCLC) cell lines. This evidence concerns the gene TMEFF2 and non-small cell lung carcinoma.